Avalyn Pharma Inc.
AVLN
$38.74
$2.165.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 68.45% | 47.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 43.68% | 49.12% | |||
| Operating Income | -43.68% | -49.12% | |||
| Income Before Tax | -43.31% | -53.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -43.31% | -53.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -43.31% | -53.51% | |||
| EBIT | -43.68% | -49.12% | |||
| EBITDA | -43.24% | -48.86% | |||
| EPS Basic | 94.46% | 65.47% | |||
| Normalized Basic EPS | 94.46% | 65.47% | |||
| EPS Diluted | 94.46% | 65.47% | |||
| Normalized Diluted EPS | 94.46% | 65.47% | |||
| Average Basic Shares Outstanding | 2,488.90% | 344.62% | |||
| Average Diluted Shares Outstanding | 2,488.90% | 344.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||